Qi Liu

Qi Liu

Auto-generated profile, based on publicly available information

Qi Liu

Office of Translational Sciences, Center for Drug Evaluation and Research U.S. Food and Drug Administration Silver Spring Maryland USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
KNKunal Naik
Kunal Naik
RGRahul K. Goyal
Rahul K. Goyal
Luca FoschiniLuca Foschini
Luca Foschini
CCChoiwai Maggie Chak
Choiwai Maggie Chak
CTChristian Thielscher
Christian Thielscher
JGJogarao Gobburu
Jogarao Gobburu

16 June 2022 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
QLQi Liu
Qi Liu
RHRuihao Huang
Ruihao Huang
JHJulie Hsieh
Julie Hsieh
HZHao Zhu
Hao Zhu
MTMo Tiwari
Mo Tiwari
SHShiew‐Mei Huang
Shiew‐Mei Huang

16 October 2021 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
QLQi Liu
Qi Liu
JSJanice B. Schwartz
Janice B. Schwartz
PSPatricia Slattum
Patricia Slattum
SLS.W. Johnny Lau
S.W. Johnny Lau
DGDaphne Guinn
Daphne Guinn
RTRobert Temple
Robert Temple

31 May 2016 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JBJulie M. Bullock
Julie M. Bullock
ARAtiqur Rahman
Atiqur Rahman
QLQi Liu
Qi Liu
Evaluation of dose plays a critical role in a successful oncology development program. Typically for oncology agents, the first-in-man phase I dose-escalation trials are conducted to determine a maximum tolerated dose (MTD). This MTD is taken forward into subsequent trials to establish the safety and efficacy of the drug product. Although this approach was appropriate historically for cytotoxics, the application of MTD as the recommend phase II dose has been problematic for the newer small molecule–targeted oncology agents. Promising alternative approaches using dose and exposure exploration, including lessons learned from recent targeted oncology agent development and approvals, are summarized and discussed. Clin Cancer Res; 22(11); 2630–8. ©2016 AACR.

12 December 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
MGMagnus Gray
Magnus Gray
RSRavi Samala
Ravi Samala
QLQi Liu
Qi Liu
DSDenny Skiles
Denny Skiles
JXJoshua Xu
Joshua Xu
LWLeihong Wu
Leihong Wu
Artificial intelligence (AI) is increasingly being used in decision making across various industries, including the public health arena. Bias in any decision‐making process can significantly skew outcomes, and AI systems have been shown to exhibit biases at times. The potential for AI systems to perpetuate and even amplify biases is a growing concern. Bias, as used in this paper, refers to the tendency toward a particular characteristic or behavior, and thus, a biased AI system is one that shows biased associations entities. In this literature review, we examine the current state of research on AI bias, including its sources, as well as the methods for measuring, benchmarking, and mitigating it. We also examine the biases and methods of mitigation specifically relevant to the healthcare field and offer a perspective on bias measurement and mitigation in regulatory science decision making.

11 January 2020 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
QLQi Liu
Qi Liu
HZHao Zhu
Hao Zhu
CLChao Liu
Chao Liu
DJDaphney Jean
Daphney Jean
SHShiew‐Mei Huang
Shiew‐Mei Huang
YWYaning Wang
Yaning Wang